NPC in the News

NPC serves as a trusted resource on issues related to biopharmaceutical innovation, patient access, the value of medicines, and more. See below for recent articles citing NPC's research and expertise. 

Podcast: The Myth of Average: Time for Change

AiArthritis Voices Podcast, April 3, 2022

Tiffany Westrich-Robertson, CEO of AiArthritis and person living with non-radiographic axial spondyloarthritis, speaks with NPC's John O'Brien about the topic of importance of innovation and treatment access in this podcast episode. 

AMCP 2022: High Out-of-Pocket Costs Are Associated with Nonadherence Among Patients Taking Oral Cancer Drugs

Managed Healthcare Executive, March 31, 2022

This articles describes NPC-sponsored research presented at the AMCP annual meeting that shows that almost half of cancer patients on oral therapies are nonadherent.

Michael Ciarametaro Talks About Balancing Drug Price Reform With Encouraging Innovation

American Journal of Managed Care, March 30, 2022

In a video interview, Michael Ciarametaro, NPC's vice president of research, discusses the balance between lowering drug prices and encouraging innovation in new drug classes for serious diseases.

AMCP 2022: Michael Ciarametaro of National Pharmaceutical Council Talks Gene Therapy, Medicaid Best Price Rule

Managed Healthcare Executive, March 30, 2022

NPC's Michael Ciarametaro speaks about gene therapy and the Medicaid Best Price Rule in a video interview during the annual AMCP conference in Chicago.

Price Transparency Healthcare Policies Reduce Out-Of-Pocket Costs

PharmaNewsIntelligence, March 18, 2022

NPC President and CEO John M. O'Brien weighs in on issues around the importance of price transparency in health care and reducing patient out-of-pocket costs to improve access to medicines.

National Pharmaceutical Council Executive to Give Hartman Lecture

The Oxford Eagle (Miss.), March 8, 2022

The local Oxford, Miss., newspaper reports on NPC President and CEO John M. O’Brien presenting the annual Charles W. Hartman Memorial Lecture on Friday, March 11, at the University of Mississippi.

ICER to Develop Annual Drug Price Hike Reports For California

InsideHealthPolicy, March 4, 2022 (subscription required)

An article about the Institute for Clinical and Economic Review (ICER) developing two reports for California cites NPC's concerns about ICER's flawed report methodology and notes that NPC President and CEO John O'Brien cautioned health policymakers in California against using the reports for policies that could harm patients.

Adopting Good Practices for High-Deductible Health Plans Can Help Employers Build Better Health Benefits

American Journal of Accountable Care, March 4, 2022

NPC and Gallagher Research & Insights discuss results from a survey demonstrating that employers are receptive to the idea of adopting good practices for health savings account-eligible high-deductible health plans (HDHPs) and, in many cases, are already implementing them. 

Experts Discuss How Employers Can Take on HSA HDHP Challenges While Encouraging Value-Based Care

American Journal of Managed Care, February 20, 2022

AJMC provides highlights from part 2 of a two-part webinar series, hosted by the National Alliance of Healthcare Purchaser Coalitions and moderated by NPC's Kimberly Westrich, focused on employer opportunities for improving value and crafting smarter deductibles in HSA-eligible HDHPs.

9 Employer Best Practices for High Deductible Health Plan Design

HealthPayerIntelligence, February 16, 2022

This article focuses on the recent report from NPC and Gallagher Research & Insights on ways employers can more effectively implement high-deductible health plans.

How Employers Can Leverage Value, Health Equity Incentives to Address Health Plan Affordability Concerns

American Journal of Managed Care, February 6, 2022

AJMC provides highlights from part 1 of a two-part webinar series, hosted by the National Alliance of Healthcare Purchaser Coalitions and featuring NPC's Kimberly Westrich, addressing issues in health care coverage affordability and how equitable health benefits and value-based design can reduce cost while improving employee engagement.

The Myth of Average: Why Individual Patient Differences Matter

American Journal of Managed Care, January 19, 2022

AJMC featured on its website NPC's newly updated booklet The Myth of Average: Why Individual Patient Differences Matter, which explores the barriers patients face when navigating the health care system.

New CMS Rule Fails to Fix Medicaid Best Price

BioCentury (subscription required), January 14, 2022

NPC's Health Affairs Forefront article "Medicaid Best Price Volatility Could Inhibit Payment Innovation" was featured in this BioCentury piece on Medicaid best price legislation impeding patient access to expensive gene therapies.

Addressing Access Burdens

Pharmaceutical Executive, January 11, 2022

NPC President and CEO John M. O'Brien discusses the increasing barriers for patients to receiving needed therapies and how pharmaceutical companies are reaching out to employers directly to talk about health benefits. 

Video: Kimberly Westrich on Micro-, Macro-Level Approaches to Improve Value-Based Benefit Design

American Journal of Managed Care, January 6, 2022

The final video in a four-part series with NPC Vice President of Health Services Research Kimberly Westrich addresses future opportunities for growth regarding value-based benefits. View part onepart two, and part three of the video series. 

NPC Appoints Sharon Phares Chief Scientific Officer

UNC Gillings School of Public Health, January 22, 2022

Pharmacy Times, January 18, 2022, January 11, 2022

STAT News, January 7, 2022

Fierce Biotech, January 7, 2022

BioSpace, January 7, 2022

Chain Drug Review, January 4, 2022

Contract Pharma, January 4, 2022

Politico Pulse, Prescription Pulse and Playbook newsletters, January 4, 2022

Pharmacy Outlook: John O’Brien, NPC

Chain Drug Review, January 3, 2022

To kick off the new year, NPC's John M. O’Brien writes in Chain Drug Review about the need for a more informed public discussion about the role that prescription drugs play in our health care system and in improving the lives of patients.